[go: up one dir, main page]

WO1998057145A1 - Systeme et methode de detection d'un etat biologique - Google Patents

Systeme et methode de detection d'un etat biologique Download PDF

Info

Publication number
WO1998057145A1
WO1998057145A1 PCT/US1998/010771 US9810771W WO9857145A1 WO 1998057145 A1 WO1998057145 A1 WO 1998057145A1 US 9810771 W US9810771 W US 9810771W WO 9857145 A1 WO9857145 A1 WO 9857145A1
Authority
WO
WIPO (PCT)
Prior art keywords
sample
radiation
laser
recited
photoacoustic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/010771
Other languages
English (en)
Inventor
Michael J. Berry
Edward Q. Yavitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrivium LLC
Original Assignee
Quadrivium LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrivium LLC filed Critical Quadrivium LLC
Priority to AU77994/98A priority Critical patent/AU7799498A/en
Publication of WO1998057145A1 publication Critical patent/WO1998057145A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/1702—Systems in which incident light is modified in accordance with the properties of the material investigated with opto-acoustic detection, e.g. for gases or analysing solids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/39—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using tunable lasers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/497—Physical analysis of biological material of gaseous biological material, e.g. breath
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/1702—Systems in which incident light is modified in accordance with the properties of the material investigated with opto-acoustic detection, e.g. for gases or analysing solids
    • G01N2021/1704—Systems in which incident light is modified in accordance with the properties of the material investigated with opto-acoustic detection, e.g. for gases or analysing solids in gases

Definitions

  • the present invention relates generally to the detection of volatile organic compounds that serve as biomarkers for a biological condition, such as a disease, and particularly to a noninvasive system and method for determining the presence of such condition in an individual or substance through analysis of a gaseous sample from the individual or substance.
  • breath analysis One potential noninvasive technique for determining the presence of a variety of diseases in the body of an individual is breath analysis. There are over three hundred distinct chemical compounds that may be detected in human expired breath, and each of these distinct chemical compounds has its own absorption spectrum. Studies have shown that specific alterations or changes in this expired air are indicative of specific diseases. This is true for some diseases because of the direct compositional relationship between constituents carried in the blood stream and constituents excreted into the alveolar spaces of the lungs. In any event, the changes or alterations in the constituents of an individual ' s breath can be detected to determine whether the individual has a particular biological condition, such as a disease or metabolic disorder.
  • the presence of a given disease can be indicated by the addition of one or more constituents in a gaseous sample, e.g., expired air, otherwise not present, a change in concentration of one or more constituents or a combination of the two.
  • a successful diagnostic technique must be able to readily detect the addition or change in concentration of constituents.
  • the addition of a constituent and/or the change in concentration of a constituent are often referred to as biochemical markers or biomarkers. Detection of biomarkers has been a complex task due to the large number of constituents within human expired air and due to the constant change of constituents that results from environmental pollutants and other components which enter an individual's lungs.
  • gas chromatography/mass spectrometry which detects the numerous components within human-expired air.
  • the use of a gas chromatographic/mass spectrometric technique has been necessary because of the number of constituents and because of their presence in sub-microgram per liter to microgram per liter concentrations.
  • Various statistical analyses are performed on the results with the aid of a personal computer to determine the presence of biomarkers. This technique, however, is expensive and time consuming, rendering it inappropriate for the routine testing of individuals .
  • the gas chromatography/mass spectrometry technique has been used in researching biomarkers associated with lung cancer.
  • Lung cancer is a disease of particular interest due to its growing presence, severe effects and difficulty of early detection.
  • Diagnostic techniques that have been used in the past to detect pre- symptomatic lung cancer include chest x-rays, fiber-optic bronchoscopy and sputum cytology. However, these techniques are costly to administer and have not been adopted as standard screening techniques . Like the gas chromatography/mass spectrometry approach, these techniques are not amenable to large-scale use for early detection of lung cancer.
  • biomarkers contained in the gases resulting from metabolic activity in cell cultures, pathology specimens or food specimens may contain biomarkers indicative of a biological condition, such as disease, spoilage or other contamination.
  • the present invention features a system and method for detecting at least one specific volatile organic compound in a gaseous sample.
  • the specific volatile organic compound is indicative of a biological condition when present in a given amount.
  • the method includes obtaining a gaseous sample that has been exposed to or is suspected of being exposed to byproducts of a biological agent.
  • An electromagnetic radiation generator is selected to generate a radiation that undergoes a characteristic intense absorption by the at least one specific volatile organic compound.
  • the radiation is directed into the sample, and any characteristic intense absorption is detected. This provides an indication of whether the biological condition exists, based on the presence and amount of the at least one specific volatile organic compound.
  • a system is provided for detecting a biomarker indicative of the presence of a biological condition.
  • the system comprises a photoacoustic cell having an inlet through which a gaseous sample may be introduced into an interior of the photoacoustic cell.
  • An electromagnetic radiation generator is combined with the photoacoustic cell and positioned to direct a radiation through the photoacoustic cell.
  • the selected radiation is of a frequency predetermined for a characteristic intense absorption by at least one specific biomarker contained in the gaseous sample.
  • the system also includes a detector coupled to the photoacoustic cell to detect the characteristic intense absorption indicative of the at least one specific biomarker. According to another aspect of the invention, a method for detecting whether a given biomarker is present in a selected gaseous sample is disclosed.
  • the method includes obtaining a gaseous sample and selecting a radiation of a type that will undergo a characteristic adsorption by a given biomarker if present in the gaseous sample.
  • the method further includes directing the radiation into the gaseous sample, and detecting whether the characteristic absorption occurs.
  • Figure 1 is a schematic illustration of a photoacoustic system according to a preferred embodiment of the present invention
  • Figure 2 is a schematic illustration of a photoacoustic cell that can be used in the system illustrated in Figure 1;
  • Figure 3 is a representation of an absorption spectrum for one biomarker indicative of lung cancer;
  • Figure 4 is a representation of another absorption spectrum of a biomarker indicative of lung cancer
  • Figure 5 is a chart showing sample bandwidths and laser lines for a carbon monoxide laser that may be used with the present invention.
  • the present invention includes a system and method for detecting biological conditions through noninvasive analysis of gaseous samples.
  • the focus of the following exemplary description is on the detection of biomarkers that are indicative of lung cancer within an individual.
  • this system and method can be modified to detect a biomarker (s) in an individual's exhaled breath indicative of other diseases, such as renal failure, liver disease or diabetes.
  • the system and method can be utilized to detect biomarkers expelled into the environment proximate cell cultures, pathology specimens, food specimens, etc., where metabolic processes occur.
  • the system and method can be used for food inspection at a processing facility to insure that the food products have not been contaminated by decay or other infestation of undesirable aerobic or anaerobic organisms. Such organisms undergo metabolic processes that release carbon dioxide or ammonia that can be detected via the present inventive system and method.
  • Biomarkers are individual constituents or combinations of constituents at given concentrations within exhaled breath that indicate a substantial likelihood of the presence of lung cancer (or other biological condition) in the individual or substance being tested.
  • biomarkers indicative of lung cancer examples include ⁇ -caprolactone (C 6 H 10 O 2 ) , 2-butanone and acetone. Studies have shown that the presence of -caprolactone in the exhaled breath of an individual indicates a ninety percent likelihood that the individual has lung cancer. Similarly, the presence of 2-butanone and the presence of acetone at given concentration levels also provide a strong indication of the presence of lung cancer within the individual. Thus, the presence of these constituents at a given concentration level in the individual ' s expired air provides a biomarker indicative of lung cancer.
  • the present invention provides a relatively simple, quick and inexpensive system and method for determining the presence of such biomarkers to allow for early screening of lung cancer.
  • the pertinent biomarkers can be determined via photoacoustic detection.
  • a radiation generating source such as a laser
  • the laser is a carbon monoxide laser tuned to a selected wavelength or wavelengths .
  • the biomarkers of interest are known to have infrared absorption spectra, and therefore the wavelength or wavelengths of the radiation is selected from within a specific band of infrared wavelengths.
  • a breath sample is placed inside a photoacoustic cell, and the radiation is directed through the cell.
  • a microphone is connected to the photoacoustic cell and exposed to the breath sample therein.
  • the microphone is able to detect absorption of the radiation by a specific biomarker via pressure changes within the photoacoustic cell.
  • the laser may be tuned to generate radiation having a wavenumber of approximately 1768 c ⁇ f 1 which corresponds to a characteristic intense absorption, e.g., an absorption peak, of ⁇ -caprolactone .
  • the radiation from the laser is chopped at a certain frequency, thereby producing a corresponding modulation of absorption of the radiation by the sample of breath within the photoacoustic cell .
  • the absorption of radiation by the biomarker results in a heating of the biomarker gas that generates an acoustic wave detectable by the microphone.
  • An acoustic signal enhancer such as helium, can be added to the sample of breath being tested to facilitate generation of this acoustic wave.
  • an electromagnetic radiation generator or radiation source 12 is used to generate a desired radiation having a wavelength or wavelengths that will be characteristically absorbed by a specific biomarker or biomarkers, if present within the gaseous sample being analyzed.
  • the sample is contained within a photoacoustic cell 14 during the analysis.
  • radiation source 12 is a continuous wave, grating-tuned carbon monoxide (CO) laser 16 connected to a high voltage power supply 18.
  • Laser 16 operates on one or more selected transitions of 12 C 16 0 and/or other isotopic variants of carbon monoxide depending on a given biomarker 's absorption spectrum and the location of its characteristic intense absorption within that spectrum.
  • the laser transitions are tuned by a diffraction grating 20 that is typically mounted on a rotation stage (not shown) as is understood by those of ordinary skill in the art.
  • the laser 16 is modulated either by voltage modulation of its high voltage power supply 18 or by a mechanical chopper 24, preferably disposed with an optical cavity 22.
  • Optical cavity 22 is located between a cavity mirror 23 of laser 16 and diffraction grating 20.
  • photoacoustic cell 14 can be disposed outside optical cavity 22, it preferably is located within optical cavity 22 to use the intracavity power of the individual laser lines. Correspondingly, this intracavity placement of the photoacoustic cell will increase the detection sensitivity of photoacoustic detection system 10, often by a factor of 100 or more.
  • a purge box 26 (shown by dashed lines) encloses photoacoustic cell 14, diffraction grating 20, chopper 24 (if used) and the end of laser 16 proximate photoacoustic cell 14.
  • Photoacoustic cell 14 can be designed in a variety of configurations to optimize its effectiveness.
  • a preferred exemplary embodiment is illustrated in Figures 1 and 2.
  • photoacoustic cell 14 includes a generally linear body 28 that lies along an axis 30 (see Figure 2) .
  • Linear body 28 preferably has a hollow interior 31 that is generally cylindrical in cross section.
  • a pair of cell windows 32 such as ZnSe windows, are mounted to linear body 28 with one window 32 at each end.
  • cell windows 32 are each mounted at Brewster ' s angle to reduce intracavity losses.
  • a microphone 34 such as an electret microphone, is coupled to photoacoustic cell 14 and exposed to its interior cavity 31 as well as any samples of breath introduced therein.
  • An exemplary microphone is a Knowles Electronics BT-1759 electret microphone.
  • An inlet/outlet port 35 is connected to linear body 28 to permit the gaseous sample, e.g., expired breath, to be introduced into interior cavity 31 and removed therefrom. Additionally, it may be desirable to introduce an acoustic signal enhancer, such as helium, into interior cavity 31. Additionally, it may also be desirable to introduce a calibration gas, such as SF 6 into interior cavity 31. Potentially, both the gaseous sample and helium can be introduced into photoacoustic cell 14 through port 35.
  • Port 35 includes a valve 36 that allows the ingress of the gaseous sample ( and, if used, the acoustic signal enhancer) but not its egress during analysis. Following analysis of the sample, valve 36 is opened and the sample is extracted or sucked from interior cavity 31. After removal of the sample, valve 36 is shut to retain a vacuum within interior cavity 31. This lower pressure allows the next gaseous sample to be expanded into photoacoustic cell 14 via the higher outside pressure that forces the sample into the lower pressure or vacuum within interior cavity 31.
  • port 35 is designed for coupling to a manifold 37 which, in turn, is designed for coupling to a sample container 38.
  • Sample container 38 may comprise a variety of configurations, such as a preevacuated flexible bag that can be filled with the desired gaseous sample within a sample collection container used to collect exhaled breath or the gases proximate other biological agents, e.g., cell cultures, pathology specimens or food specimens, that potentially have been exposed to byproducts of the metabolism of the biological agent. In the case of breath analysis, the individual (biological agent) potentially can exhale directly into the flexible bag to provide the sample for analysis.
  • the container 38 preferably includes a valved port to permit entry of the sample and prevent any leakage or unwanted contamination.
  • Manifold 37 includes a connection port 39, designed for mating engagement with port 35.
  • Manifold 37 also includes a helium port 40, a sample port 41 and an evacuation port 42.
  • a helium supply 43 (see Figure 2) may be attached to helium port 40; sample container 38 may be attached to sample port 41; and a vacuum pump (not shown) may be attached to evacuation port 42.
  • a valve 44 is disposed in each port 40 and 41 to permit inflow of the helium and the breath sample.
  • a similar valve 44 is disposed in evacuation port 42 to facilitate evacuation of manifold 37, interior cavity 31 and the "dead space" between valves .
  • Sample container 38 includes an outlet port 45 designed for sealing engagement with sample port 41 of manifold 37.
  • Outlet port 45 can also serve as the port through which the sample is admitted into container 38, or a separate inlet port can be provided depending on the specific application.
  • outlet port 45 includes a contoured surface 46, such as a tapered octagonal or hexagonal surface that is designed for mating engagement with a corresponding contoured surface of sample port 41. This will help ensure that only the desired sample container 38 is connected to manifold 37 and ultimately photoacoustic cell 14. After making the connections, the sample of breath can be expanded or otherwise forced into interior cavity 31 of photoacoustic cell 14.
  • photoacoustic cell potentially can be designed with separate inlet and outlet ports connected to body 28.
  • sample container 38 includes a valve 47 disposed in outlet port 45.
  • the helium supply 43 includes a valve 48. This permits a sample of breath to be introduced into interior cavity 31 of photoacoustic cell 14 as follows: Manifold 37 is connected to port 35 of photoacoustic cell 14 via connection port 39. Sample container 38, with valve 47 closed, is connected to sample port 41 via outlet port 45, helium supply 43, with valve 48 closed, is connected to helium port 40, and a vacuum is applied at evacuation port 42. Valves 47 and 48 remain closed, and valve 36 as well as valves 44 are opened to evacuate interior cavity 31 and manifold 37 via the vacuum applied at evacuation port 42.
  • valve 44 of evacuation port 42 is closed, and valve 47 of sample container 38 is opened to permit expansion of the gaseous sample into interior cavity 31 of photoacoustic cell 14.
  • Valve 47 may then be closed and valve 48 opened to permit the flow of helium into interior cavity 31.
  • the helium is at a higher pressure than the gaseous sample, so it will readily flow into photoacoustic cell 14.
  • a pressure gauge (not shown) may be connected to manifold 37 for monitoring both the sample pressure and the helium pressure to facilitate preparation of reproducible and/or optimized mixtures in interior cavity 31.
  • the exact method for handling and testing the gaseous sample may vary depending on the type of photoacoustic cell and/or manifold that is used and whether an acoustic signal enhancer, such as helium, and/or a calibration gas, such as SF 6 is combined with the sample.
  • an acoustic signal enhancer such as helium
  • a calibration gas such as SF 6
  • Water vapor removal can be accomplished while the sample is contained in sample container 38 by including a desiccant
  • Microphone 34 is designed to detect pressure changes within photoacoustic cell 14.
  • the pressure changes result from the heating of specific gaseous constituents, i.e., biomarkers, that may be present in the sample of breath undergoing an analysis within interior cavity 31.
  • biomarkers i.e., biomarkers
  • These pressure changes in photoacoustic cell 14 result from the characteristic intense absorption by one or more of the biomarkers.
  • a specific biomarker 's characteristic intense absorption is a substantially increased absorption of the radiation generated at a specific frequency by laser 16 and directed through photoacoustic cell 14.
  • a photodetector 51 is employed to monitor the power of laser 16 within photoacoustic cell 14. Photodetector 51 is used to help compensate for changes detected by microphone 34 due to changes in the power of radiation generated by laser 16.
  • microphone 34 is coupled to an amplifier 52 preferably via a preamplifier 54 which receives the signal provided by microphone 34.
  • photodetector 51 is coupled to and provides a signal to an amplifier 56.
  • the preamplifier 54/amplifier 52 combination detects and conditions microphone signals at the selected modulation frequency which optimizes the signal-to-noise ratio.
  • Amplifiers 52 and 56 are preferably lock-in amplifiers which provide synchronous detection and reduce the influence of extraneous effects, such as noise, on the measurement of both the pressure changes within photoacoustic cell 14 and the radiation generated by laser 16.
  • the modulation of the radiation emitted by laser 16 is synchronized with the gating of amplifiers 52 and 56. This may be accomplished by providing a reference signal 58 from the modulation source (e.g., chopper 24, if used, or voltage modulated high voltage power supply 18) . Reference signal 58 is directed to lock- in amplifiers 52 and 56 which are able to detect signals that are synchronous with the modulation (i.e., at the same modulation frequency, with or without a phase shift) . The amplified signals from amplifiers 52, 56 are directed to a ratiometer 60 that, in turn, provides an output signal which is effectively a measure of the ratio of the signal detected by microphone 34 divided by the signal detected by photodetector 51.
  • a ratiometer 60 that, in turn, provides an output signal which is effectively a measure of the ratio of the signal detected by microphone 34 divided by the signal detected by photodetector 51.
  • the signal is a measure of the fraction of the total input radiation that is absorbed by a given biomarker or biomarkers within photoacoustic cell 14.
  • This signal may then be directed to a data acquisition, analysis and display system 62 that is able to record, process, analyze and/or display the ratioed photoacoustic signal, as would be understood by one of ordinary skill in the art.
  • the signal provided by microphone 34 can be further enhanced by introducing an acoustic modifier, such as helium, into photoacoustic cell 14 along with the sample being analyzed.
  • photoacoustic detection system 10 provides very sensitive measurements, and has the ability to detect the presence of constituents that may only appear within the sample in parts per billion by volume.
  • photoacoustic detection system 10 also can accurately detect the concentration levels of constituents within the gaseous sample. This is important for some constituents where changes in concentration from a normal level serve as a biomarker for the presence of a biological condition, such as lung cancer or other disease.
  • the concentration or density of a specific constituent is determined by measuring the signal strength of the signal detected by microphone 34 and comparing this to the signal strength (s) of a reference sample or samples of known concentration (s) , as is understood in the art.
  • Photoacoustic cell 14 is first calibrated using a reference sample or samples to measure signal levels provided by microphone 34 for known concentrations of the subject constituent. Over a broad range of concentrations, the photoacoustic signal level is linearly related to the concentration of a given dilute constituent within a sample mixture containing the constituent plus the acoustic signal enhancer, if used, all at a fixed total pressure. The concentration or density of the subject constituent within the sample can then accurately and readily be determined based on comparing the signal strength of the acoustic wave created from the constituent's characteristic absorption to those of the reference sample or samples.
  • One exemplary implementation of the present invention provides a method for detecting lung cancer in an individual, and includes analysis of a sample of the individual ' s breath to detect one or more lung cancer biomarkers.
  • the sample may, for example, be originally provided by the individual via blowing into a sample container, such as sample container 38.
  • the sample then can be analyzed or sent, e.g., mailed, to a central processing location where it is obtained for analysis.
  • a laser or other appropriate radiation source is selected to generate a radiation that undergoes the characteristic intense absorption by the biomarker of interest.
  • the radiation is directed into the sample of breath, and a detector, such as microphone 34, detects whether the characteristic absorption of the radiation occurs.
  • a detector such as microphone 34.
  • FIGs 3-4 representative absorption spectra of specific biomarkers indicative of lung cancer are illustrated.
  • a representative absorption spectrum for a lactone, specifically ⁇ -caprolactone shows the absorbance of this biomarker versus the wavenumber of the radiation for a particular concentration and path length of this chemical compound.
  • a characteristic intense absorption 64 occurs when the constituent is struck by radiation having a wavenumber of approximately 1768 cmN Assuming there is no interference, i.e., overlapping absorption spikes, from other constituents within the sample of breath, laser 16 can be tuned to emit radiation with a wavenumber, e.g., approximately 1768 cm "1 , to match the characteristic intense absorption 64 of the biomarker ⁇ -caprolactone .
  • This characteristic absorption within photoacoustic cell 14 creates a pressure pulse detected by microphone 34.
  • microphone 34 provides a signal that is ultimately displayed on unit 62 to indicate the presence of biomarker ⁇ -caprolactone and the consequent probability of lung cancer in the individual from which the sample of breath originated.
  • a biomarker such as ⁇ -caprolactone
  • ⁇ -caprolactone is normally a constituent in exhaled breath only when the individual has lung cancer. Thus, detecting its mere presence in the sample of breath is a strong biomarker indicative of lung cancer. Additionally, there appears to be little if any interference between the characteristic intense absorption of ⁇ -caprolactone and that of other constituents within exhaled breath, provided the water vapor is removed from the breath sample. Thus, photoacoustic detection system 10 can be used to simply detect the presence of this constituent within the sample of breath to provide an indication of lung cancer.
  • acetone may appear in the expired air of individuals without lung cancer. However, this constituent still provides an indication or a biomarker of lung cancer when it appears at certain densities or concentrations within the exhaled breath of the test subject.
  • concentration of acetone can readily be determined, as described above, once the photoacoustic signal level is properly calibrated using a reference mixture or mixtures, as known by those of ordinary skill in the art.
  • acetone undergoes a characteristic intense absorption 66 in the presence of radiation having a wavenumber of approximately 1740 cm "1 .
  • laser 16 is tuned to emit radiation having a wavenumber of approximately 1740 cm "1 .
  • this causes the characteristic absorption within the sample and creates an acoustic wave within photoacoustic cell 14 that is detected by microphone 34.
  • the signal strength can be compared to the signal strength of a reference sample of known concentration to determine the density of acetone within the sample.
  • the acetone serves as a biomarker indicative of lung cancer within the individual .
  • the optimum characteristic intense absorption may not be the maximum absorption because of interference at that wavenumber.
  • laser 16 can be finely tuned to emit radiation having the desired wavenumber. In fact, it is often desirable to detect the presence, and possibly the concentration, of more than one biomarker. This may be accomplished by appropriately tuning laser 16 to emit the desired radiation for each biomarker sought.
  • laser 16 is a carbon monoxide laser having great flexibility with respect to control over the wavenumber at which radiation is emitted.
  • the illustrative chart in Figure 5 is based on the 1 C 16 0 isotope of carbon monoxide, but numerous adjustments to the position of the laser lines within a given vibrational band, and consequently the wavenumber of the radiation emitted, can be made by choosing other isotopic variants of carbon monoxide. This permits laser 16 to be accurately tuned to emit radiation having a desired wavenumber for absorption by a biomarker even if the characteristic intense absorption of that biomarker is spread over a small range of wavenumbers or fractions of wavenumbers.
  • the interfering constituents can be removed from the sample prior to analysis.
  • water vapor which tends to show substantial absorption at a wide range of wavenumbers, can be removed by an appropriate desiccant.
  • other constituents can be removed, prior to analysis, with appropriate adsorbents.
  • the interfering constituents are not always amenable to early removal . In these situations, it may be necessary to determine the photoacoustic signal contributions of each of the interfering gases within the sample.
  • the gases of interest will tend to have interfering absorption spectra over a definite range of wavenumbers, and the actual gases involved can be determined from the various known absorption spectra of the constituents found in exhaled breath or other gaseous sample .
  • laser 16 is adjusted to emit radiation having a predetermined wavenumber.
  • the radiation is directed through photoacoustic cell 14 and the photoacoustic signal is measured. This procedure is repeated at different predetermined wavenumbers .
  • the number of wavenumbers should be at least one greater than the sum of the number of biomarkers plus the number of interfering gases whose photoacoustic signal contributions are of interest .
  • the predetermined wavenumbers of the radiation are chosen for strong absorption by each of the different gaseous constituents of interest.
  • the overall photoacoustic signal measured for each radiation having a given wavenumber can be treated as the linear sum of photoacoustic signal contributions by each relevant constituent of the sample. This can be described in algebraic form as follows:
  • S. the total photoacoustic signal provided by the mixture at a radiation having a given wavenumber j
  • n the number of constituents i in the mixture
  • s 1D the photoacoustic signal contribution for a particular constituent i, i.e. gas, at a particular wavenumber j
  • Each photoacoustic signal contribution s ⁇ ;) of constituent i at wavenumber j is the product of a concentration for that constituent c times its signal contribution at wavenumber j per unit concentration ⁇ ⁇ : :
  • the quantity ⁇ ⁇ : is termed the "normalized photoacoustic signal contribution" .
  • the normalized photoacoustic signal contribution for each constituent i at each wavenumber j can be determined by measuring photoacoustic spectra
  • the concentrations of each of the constituents c. can be determined by, for example, least squares minimization of the residuals of calculated vs . measured total photoacoustic signal measurements S : as a function of trial values c..
  • the calculations are typically performed on a processor or computer incorporated into unit 62 of photoacoustic system 10.
  • the density or concentration of the constituents can be used to determine whether a biomarker indicative of a particular disease is present. If multiple interfering biomarkers are potentially present, this type of analysis also can be used to determine the concentrations of those multiple biomarkers .
  • Another exemplary procedure involves the use of a continuous wave (cw) CO laser operating in the 2.6 to 4.0 ⁇ m spectral region.
  • Use of this spectral region helps avoid spectral interference from water vapor and other contaminants in determining VOCs present in the gaseous sample, e.g., breath sample, cell culture sample, food specimen sample, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)

Abstract

L'invention concerne un système (10) et un procédé permettant la détection précoce d'états biologiques, notamment de maladies, par l'analyse d'échantillons de gaz appropriés. Le système (10) et le procédé servent en particulier au dépistage précoce des maladies, telles que le cancer du poumon, par détection de biomarqueurs spécifiques lorsqu'ils sont présents dans l'air expiré par un individu ou dans des échantillons de gaz prélevés à proximité de cultures de cellules, d'échantillons pathologiques, ou d'échantillons de nourriture. Le système de réalisation préféré de l'invention met en oeuvre un laser (16) au monoxyde de carbone qui émet un rayonnement et le dirige sur une cellule photo-acoustique (14). Ce type de rayonnement provoque l'absorption intense d'une caractéristique par le biomarqueur, pour autant que ce dernier soit présent dans l'échantillon de gaz. L'absorption du rayonnement est détectée de manière acoustique.
PCT/US1998/010771 1997-06-10 1998-06-09 Systeme et methode de detection d'un etat biologique Ceased WO1998057145A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU77994/98A AU7799498A (en) 1997-06-10 1998-06-09 System and method for detection of a biological condition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87202997A 1997-06-10 1997-06-10
US08/872,029 1997-06-10

Publications (1)

Publication Number Publication Date
WO1998057145A1 true WO1998057145A1 (fr) 1998-12-17

Family

ID=25358680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/010771 Ceased WO1998057145A1 (fr) 1997-06-10 1998-06-09 Systeme et methode de detection d'un etat biologique

Country Status (2)

Country Link
AU (1) AU7799498A (fr)
WO (1) WO1998057145A1 (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049922A1 (fr) * 1998-01-07 2000-11-08 Stichting voor de Technische Wetenschappen Procede de determination par spectroscopie d'un compose organique volatil dans un gaz rejete par un mammalien
DE10028548C1 (de) * 2000-06-09 2001-08-30 Inst Chemo Biosensorik Verfahren zum Nachweis von alpha-Oxoaldehyden in Vollblut, Blutplasma und/oder Serum eines Patienten
DE10217033A1 (de) * 2002-04-11 2003-11-06 Shanta Banerjee Verfahren und Diagnose von Prädiabetes und Diabetes mellitus anhand von Atemluftuntersuchungen
DE10231541A1 (de) * 2002-07-11 2004-01-29 Gäbler, Ralph, Dr. Verfahren zur Bestimmung der Reaktion eines biologischen Systems
US6974706B1 (en) 2003-01-16 2005-12-13 University Of Florida Research Foundation, Inc. Application of biosensors for diagnosis and treatment of disease
US6981947B2 (en) 2002-01-22 2006-01-03 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring respiratory gases during anesthesia
US7052854B2 (en) 2001-05-23 2006-05-30 University Of Florida Research Foundation, Inc. Application of nanotechnology and sensor technologies for ex-vivo diagnostics
US7052468B2 (en) 2001-05-24 2006-05-30 University Of Florida Research Foundation, Inc. Method and apparatus for detecting environmental smoke exposure
US7104963B2 (en) 2002-01-22 2006-09-12 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath
WO2007079508A1 (fr) * 2006-01-13 2007-07-19 Bernard Douet Procédé et dispositif permettant de déterminer l'état d'une matière biologique, en particulier d'un aliment
US7306953B2 (en) 2002-07-18 2007-12-11 The University Of The West Of England, Bristol Detection of disease by analysis of emissions
DE102007054157A1 (de) * 2007-11-12 2009-05-28 Manfred Dausch Vorrichtung und Verfahren zur Analyse eines in einem Behälter aufgenommenen Gases oder Gasgemisches
JP2009282041A (ja) * 1999-05-28 2009-12-03 Cepheid 化学反応を制御するためのカートリッジ
US7820108B2 (en) 1999-11-08 2010-10-26 University Of Florida Research Foundation, Inc. Marker detection method and apparatus to monitor drug compliance
US7914460B2 (en) 2006-08-15 2011-03-29 University Of Florida Research Foundation, Inc. Condensate glucose analyzer
WO2012006704A1 (fr) 2010-07-16 2012-01-19 Universidade De São Paulo- Usp Procédé non invasif pour diagnostiquer la gravité d'une insuffisance cardiaque, utilisation d'un biomarqueur pour diagnostiquer une insuffisance cardiaque décompensée, dispositif destiné à collecter le biomarqueur d'insuffisance cardiaque à partir de l'air expiré et trousse de diagnostic
US8211035B2 (en) 2002-01-22 2012-07-03 University Of Florida Research Foundation, Inc. System and method for monitoring health using exhaled breath
US20120266653A1 (en) * 2005-12-06 2012-10-25 Applied Nanotech Holdings, Inc. Analysis of gases
EP2001534A4 (fr) * 2006-03-07 2013-07-03 Univ Florida Système de suivi d'adhésion aux médicaments
CN104034666A (zh) * 2014-06-13 2014-09-10 江西科技师范大学 一种食品药品质量分级快速检测装置及方法
US9541537B1 (en) 2015-09-24 2017-01-10 Frito-Lay North America, Inc. Quantitative texture measurement apparatus and method
JP2017062221A (ja) * 2015-01-30 2017-03-30 Toto株式会社 生体情報測定システム
US9678015B2 (en) 2014-09-26 2017-06-13 Frito-Lay North America, Inc. Method for elemental analysis of a snack food product in a dynamic production line
WO2017153765A1 (fr) * 2016-03-09 2017-09-14 Fraunhofer Uk Research Ltd Détecteur photo-acoustique
US10070661B2 (en) 2015-09-24 2018-09-11 Frito-Lay North America, Inc. Feedback control of food texture system and method
US10107785B2 (en) 2015-09-24 2018-10-23 Frito-Lay North America, Inc. Quantitative liquid texture measurement apparatus and method
US10598648B2 (en) 2015-09-24 2020-03-24 Frito-Lay North America, Inc. Quantitative texture measurement apparatus and method
CN110958853A (zh) * 2017-06-02 2020-04-03 威拉赛特公司 用于鉴定或监测肺病的方法和系统
US10969316B2 (en) 2015-09-24 2021-04-06 Frito-Lay North America, Inc. Quantitative in-situ texture measurement apparatus and method
US11243190B2 (en) 2015-09-24 2022-02-08 Frito-Lay North America, Inc. Quantitative liquid texture measurement method
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNEGGER S., SIGRIST M. W.: "LONGITUDINAL RESONANT SPECTROPHONE FOR CO-LASER PHOTOACOUSTIC SPECTROSCOPY.", APPLIED PHYSICS B. PHOTOPHYSICS AND CHEMISTRY., SPRINGER VERLAG. HEIDELBERG., DE, vol. 44., 1 January 1987 (1987-01-01), DE, pages 125 - 132., XP002910603, DOI: 10.1007/BF00694205 *
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 126:128980, XP002910602 *
O'NEILL H. J., ET AL.: "A COMPUTERIZED CALSSIFICATION TECHNIQUE FOR SCREENING FOR THE PRESENCE OF BREATH BIOMARKERS IN LUNG CANCER.", CLINICAL CHEMISTRY., AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC., vol. 34., no. 08., 1 January 1988 (1988-01-01), WASHINGTON, DC., pages 1613 - 1618., XP002910601, ISSN: 0009-9147 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049922A1 (fr) * 1998-01-07 2000-11-08 Stichting voor de Technische Wetenschappen Procede de determination par spectroscopie d'un compose organique volatil dans un gaz rejete par un mammalien
JP2009282041A (ja) * 1999-05-28 2009-12-03 Cepheid 化学反応を制御するためのカートリッジ
US7820108B2 (en) 1999-11-08 2010-10-26 University Of Florida Research Foundation, Inc. Marker detection method and apparatus to monitor drug compliance
DE10028548C1 (de) * 2000-06-09 2001-08-30 Inst Chemo Biosensorik Verfahren zum Nachweis von alpha-Oxoaldehyden in Vollblut, Blutplasma und/oder Serum eines Patienten
US6884223B2 (en) 2000-06-09 2005-04-26 Institut Fur Chemo-Und Biosensorik Munster E.V. Method for detecting α-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient
US7052854B2 (en) 2001-05-23 2006-05-30 University Of Florida Research Foundation, Inc. Application of nanotechnology and sensor technologies for ex-vivo diagnostics
US7052468B2 (en) 2001-05-24 2006-05-30 University Of Florida Research Foundation, Inc. Method and apparatus for detecting environmental smoke exposure
US7104963B2 (en) 2002-01-22 2006-09-12 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath
US6981947B2 (en) 2002-01-22 2006-01-03 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring respiratory gases during anesthesia
US8211035B2 (en) 2002-01-22 2012-07-03 University Of Florida Research Foundation, Inc. System and method for monitoring health using exhaled breath
DE10217033A1 (de) * 2002-04-11 2003-11-06 Shanta Banerjee Verfahren und Diagnose von Prädiabetes und Diabetes mellitus anhand von Atemluftuntersuchungen
DE10231541A1 (de) * 2002-07-11 2004-01-29 Gäbler, Ralph, Dr. Verfahren zur Bestimmung der Reaktion eines biologischen Systems
US7306953B2 (en) 2002-07-18 2007-12-11 The University Of The West Of England, Bristol Detection of disease by analysis of emissions
US6974706B1 (en) 2003-01-16 2005-12-13 University Of Florida Research Foundation, Inc. Application of biosensors for diagnosis and treatment of disease
US20120266653A1 (en) * 2005-12-06 2012-10-25 Applied Nanotech Holdings, Inc. Analysis of gases
WO2007079508A1 (fr) * 2006-01-13 2007-07-19 Bernard Douet Procédé et dispositif permettant de déterminer l'état d'une matière biologique, en particulier d'un aliment
EP2001534A4 (fr) * 2006-03-07 2013-07-03 Univ Florida Système de suivi d'adhésion aux médicaments
US7914460B2 (en) 2006-08-15 2011-03-29 University Of Florida Research Foundation, Inc. Condensate glucose analyzer
DE102007054157A1 (de) * 2007-11-12 2009-05-28 Manfred Dausch Vorrichtung und Verfahren zur Analyse eines in einem Behälter aufgenommenen Gases oder Gasgemisches
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
US12297503B2 (en) 2009-05-07 2025-05-13 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
WO2012006704A1 (fr) 2010-07-16 2012-01-19 Universidade De São Paulo- Usp Procédé non invasif pour diagnostiquer la gravité d'une insuffisance cardiaque, utilisation d'un biomarqueur pour diagnostiquer une insuffisance cardiaque décompensée, dispositif destiné à collecter le biomarqueur d'insuffisance cardiaque à partir de l'air expiré et trousse de diagnostic
US8747325B2 (en) 2010-07-16 2014-06-10 Fundacao De Amparo A Pesquisa Do Estado De Sao Paulo (Fapesp) Non-invasive method for diagnosing the severity of heart failure by extracting and analyzing acetone concentrations in captured exhaled breath
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN104034666A (zh) * 2014-06-13 2014-09-10 江西科技师范大学 一种食品药品质量分级快速检测装置及方法
US9678015B2 (en) 2014-09-26 2017-06-13 Frito-Lay North America, Inc. Method for elemental analysis of a snack food product in a dynamic production line
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
JP2017062221A (ja) * 2015-01-30 2017-03-30 Toto株式会社 生体情報測定システム
US10969316B2 (en) 2015-09-24 2021-04-06 Frito-Lay North America, Inc. Quantitative in-situ texture measurement apparatus and method
US11243190B2 (en) 2015-09-24 2022-02-08 Frito-Lay North America, Inc. Quantitative liquid texture measurement method
US10598648B2 (en) 2015-09-24 2020-03-24 Frito-Lay North America, Inc. Quantitative texture measurement apparatus and method
US10107785B2 (en) 2015-09-24 2018-10-23 Frito-Lay North America, Inc. Quantitative liquid texture measurement apparatus and method
US10070661B2 (en) 2015-09-24 2018-09-11 Frito-Lay North America, Inc. Feedback control of food texture system and method
US9541537B1 (en) 2015-09-24 2017-01-10 Frito-Lay North America, Inc. Quantitative texture measurement apparatus and method
WO2017153765A1 (fr) * 2016-03-09 2017-09-14 Fraunhofer Uk Research Ltd Détecteur photo-acoustique
CN110958853A (zh) * 2017-06-02 2020-04-03 威拉赛特公司 用于鉴定或监测肺病的方法和系统
CN110958853B (zh) * 2017-06-02 2023-08-25 威拉赛特公司 用于鉴定或监测肺病的方法和系统

Also Published As

Publication number Publication date
AU7799498A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
US6363772B1 (en) System and method for detection of a biological condition
WO1998057145A1 (fr) Systeme et methode de detection d'un etat biologique
US7300408B2 (en) Spectroscopic breath analysis
US6202470B1 (en) System and method for isotope ratio analysis and gas detection by photoacoustics
Cao et al. Current status of methods and techniques for breath analysis
CA2277945C (fr) Mesure isotopique stable et procede de mesure spectroscopique
US5515859A (en) Myocardial infarction and ischemia detection method and apparatus
EP0556614A1 (fr) Procédé et appareil pour l'analyse isotopique
EP0758084A2 (fr) Procédé de mesure optique des composants d'un gaz expiré
JP4966208B2 (ja) 全有機炭素のための呼吸気検査
US8237927B1 (en) Multi-color cavity ringdown based detection method and apparatus
US20090124918A1 (en) Apparatus For Spectroscopically Analyzing A Gas
GB1576141A (en) Method and apparatus for pulmonary function analysis
US20040137637A1 (en) Breath gas analyzer for diagnosing diabetes and method of use thereof
Mürtz Breath diagnostics using laser spectroscopy
CN100481309C (zh) 用于检测有机体和天然产品状态以及分析具有主要和次要成分的气体混合物的方法和装置
US20220287588A1 (en) Universal portable breath content alayzer
CN114235742A (zh) 基于呼吸气体大类标志物复合光谱检测系统及方法
Li et al. WMS based dual-range real-time trace sensor for ethane detection in exhaled breath
Pangerl et al. A sub-ppbv-level acetone and ethanol quantum cascade laser based photoacoustic sensor–characterization and multi-component spectra recording in synthetic breath
US5272907A (en) Method for the identification of gases
US6072577A (en) Noble gas detection and determination
US20140179809A1 (en) Determination Of Location Of Bacterial Load In The Lungs
JP4452783B2 (ja) 呼気分析装置を用いた肝硬変検査方法及び装置
Arnoudse et al. Instrumentation for the breath-by-breath determination of oxygen and carbon dioxide based on nondispersive absorption measurements

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999502545

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA